SCHEMBL247470

SCHEMBL247470

COc1cncc(-c2cnc(N3CCOCC3)cc2Nc2c(C)c(-c3ccccn3)nc3c(C)ccc(F)c23)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 7/20 0.46
PIK3CD O00329 2/20 0.45
ATR Q13535 2/20 0.40
ATRIP Q8WXE1 2/20 0.40
ABL1 P00519 1/20 0.37
NTRK1 P04629 1/20 0.37
YES1 P07947 1/20 0.37
PIM1 P11309 1/20 0.37
MAPK1 P28482 1/20 0.37
KDR P35968 1/20 0.37
HIPK1 Q86Z02 1/20 0.37
FYN P06241 1/20 0.36
TGFBR1 P36897 2/20 0.36
PIK3CB P42338 1/20 0.35
ROS1 P08922 2/20 0.35
RAF1 P04049 1/20 0.35
BRAF P15056 1/20 0.35
MTOR P42345 1/20 0.34
SMG1 Q96Q15 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL248473 0.93 PIK3CD (0.44) PIK3CAPIK3CDATRATRIPABL1
SCHEMBL247262 0.90 PIK3CD (0.50) PIK3CAPIK3CDATRATRIPABL1
SCHEMBL245595 0.88 PIK3CD (0.41) PIK3CAPIK3CDATRATRIPABL1
SCHEMBL249060 0.88 PIK3CD (0.60) PIK3CAPIK3CDATRATRIPABL1
SCHEMBL248111 0.84 PIK3CD (0.47) PIK3CAPIK3CDATRATRIPPIK3CB
SCHEMBL248832 0.84 ATR (0.42) PIK3CAPIK3CDATRATRIPABL1
SCHEMBL2711363 0.80 PIK3CD (0.55) PIK3CAPIK3CDABL1NTRK1YES1
SCHEMBL247672 0.80 PIK3CD (0.50) PIK3CAPIK3CDPIK3CB
SCHEMBL247237 0.80 PIK3CD (0.63) PIK3CAPIK3CDATRATRIPPIK3CB
SCHEMBL2713399 0.78 PIK3CD (0.65) PIK3CAPIK3CDABL1NTRK1YES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588471-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY Amgen Inc. (US) 2013-05-08 EP disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 PIK3CA 28/4885PIK3CD 24/4885ATR 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.